Medically reviewed by Jerome Albert Ecker | MD, Assistant Professor of Medicine, Duke University - Durham, NC on November 5th, 2023.
These disorders occur when bone marrow produces abnormal, immature blood cells that cannot function properly, affecting approximately 4 out of every 100,000 people annually with median age at diagnosis being 70.
Complete blood count typically shows low red blood cells (anemia below 10 g/dL), low white blood cells (under 1,800/μL), and low platelets (under 100,000/μL), creating the classic triad of fatigue, infections, and bleeding.
Previous chemotherapy or radiation therapy increases risk 10-fold, with secondary cases developing 2-8 years after cancer treatment and carrying a worse prognosis than primary forms.
Hypomethylating agents like azacitidine and decitabine can extend survival by 6-9 months compared to supportive care alone, while allogeneic stem cell transplant offers the only curative option for eligible patients under 70.
Bone marrow biopsy revealing dysplastic changes in cell morphology and cytogenetic abnormalities helps classify risk using the Revised International Prognostic Scoring System, determining whether patients need immediate treatment or can safely monitor.
Myelodysplastic syndromes (MDS) are a rare group of blood disorders that occur when the bone marrow fails to produce enough healthy blood cells. The bone marrow is the spongy material inside the bones responsible for creating red blood cells, white blood cells, and platelets. In MDS, the bone marrow produces low numbers of blood cells, leading to low counts of red blood cells, white blood cells, and/or platelets or defective ones, leading to various health issues. Patients with MDS are at risk for developing acute myeloid leukemia (AML).
MDS primarily affects people aged 65 and older, with men being more susceptible than women. However, younger individuals can also develop the condition. Some factors that increase the risk of developing MDS include:
Previous cancer therapy (chemotherapy or radiation)
Smoking
Exposure to benzene, a chemical used in plastics and dyes, heavy metals, tobacco smoke, and aggricultural chemicals/pesticides
Inherited conditions like Down syndrome, Fanconi anemia, and others
Certain blood diseases, such as paroxysmal nocturnal hemoglobinuria and congenital neutropenia
In the early stages of MDS, individuals may not experience any symptoms. As the condition progresses, the following symptoms may appear:
Constant fatigue and weakness due to anemia (low red blood cell count)
Unusual bleeding or bruising
Tiny red marks under the skin (petechiae)
Paleness
Shortness of breath during physical activity
Frequent infections
Bone pain
Mouth ulcers
Weight loss
To diagnose MDS, your doctor will start by reviewing your medical history and conducting a physical examination. They may also perform the following tests:
Blood tests to count the different types of blood cells
Bone marrow biopsy to analyze the cells and check for genetic abnormalities
Genetic analysis of the bone marrow cells
Based on the results, your doctor will determine the specific type of MDS you have, which can help predict the progression of the disease and guide treatment decisions.
The treatment for MDS depends on the type and severity of the condition. Some common treatment options include:
Watchful waiting for mild cases with regular check-ups
Low-intensity treatments:
Chemotherapy drugs
Immunosuppressive therapy
Blood transfusions
Iron chelation therapy
Growth factors
Hypomethylating agents (azacitidine, decitabine)
Targeted therapy (luspatercept)
High-intensity treatments:
Stem cell transplant (the only potential cure for MDS)
Combination chemotherapy
Your healthcare team will work with you to determine the most appropriate treatment plan based on your specific case and overall health.
If you suspect you or a loved one may have myelodysplastic syndrome, it's essential to consult a healthcare professional for an accurate diagnosis and personalized treatment plan. With proper care and management, many individuals with MDS can maintain a good quality of life.
For more information on myelodysplastic syndromes, visit:
Early recognition of persistent cytopenias (low blood counts) is crucial since 30% of cases progress to acute leukemia within 2 years without treatment. Prompt bone marrow evaluation can identify candidates for potentially life-extending therapies or curative transplant. If you're experiencing unexplained fatigue, frequent infections, or easy bruising, Doctronic can help connect you with hematology specialists for proper evaluation.
When most people think of preeclampsia, they immediately associate it with dangerously high blood pressure during pregnancy. However, a lesser-known but equally serious [...]
Read MorePanic attacks represent some of the most frightening experiences a person can endure, striking suddenly with overwhelming physical and psychological symptoms. These intense [...]
Read MoreWhen sleepless nights become a regular occurrence, over-the-counter sleep aids offer an accessible first line of defense against insomnia. Nearly one-third of adults [...]
Read More
